RMTI Rockwell Medical

Richmond Brothers Comments on Appointment of John G. Cooper to Rockwell Medical, Inc. Board

Richmond Brothers, Inc., a Michigan-based SEC registered investment advisor and wealth management firm that is the largest beneficial owner of Rockwell Medical, Inc. (NASDAQ: RMTI) (“Rockwell” or the “Company”), which together with its affiliates beneficially owns nearly 5.6 million shares, or 10.8% of the Company’s outstanding common stock, today issued the following statement in response to Rockwell’s appointment of John G. Cooper to its Board of Directors.

“We are cautiously optimistic that Mr. Cooper can bring sorely-needed additional independent perspective to Rockwell’s Board. We hope that Mr. Cooper takes his fiduciary duty seriously and acts in the best interests of all shareholders. To that end, we will be monitoring Mr. Cooper’s performance on the Board and that of the Company as a whole to determine if he will exert adequate oversight of management and act as an independent check to Chairman and CEO Rob Chioini. Ideally, Mr. Cooper’s addition, following the addition of Mark H. Ravich and the earlier appointment of Dr. Robin Smith, can help move the Rockwell Board in a more independent direction.

As we have consistently stated, we believe that Rockwell needs swift change to improve its woeful corporate governance and ensure it is executing against a strategy to drive value for shareholders. From what we have seen, we are extremely skeptical of Mr. Chioini’s willingness to keep his Board members informed about management’s activities and allow them to successfully fulfill their fiduciary duty to push for such improvements. We believe all the independent Directors of Rockwell, hopefully including Mr. Cooper and Dr. Robin Smith, in addition to Mark H. Ravich, should demand that Mr. Chioini grant all Directors appropriate access to Rockwell’s books and records and key personnel – access which has not been provided to Mr. Ravich to date.

We also call on the independent members of Rockwell’s Board to take a fresh look at the Company’s strategy to achieve transitional add-on (TAO) reimbursement for Triferic. In our view, the Board, and Rockwell shareholders, would be mistaken in thinking that achieving TAO pricing for Triferic is an indication of anything other than luck on Mr. Chioini’s part. We believe that Mr. Chioini lacks the skills and ability needed to drive a successful strategy at the Company, and would be equally ill equipped to manage Rockwell’s assets and potential should Triferic achieve TAO pricing. Given this, and given Mr. Chioini’s pointed unresponsiveness to shareholder concerns, we again call for him to resign or be removed.”



About Richmond Brothers, Inc.

Richmond Brothers, Inc. is an SEC registered investment advisor and wealth management firm founded in 1994.

EN
08/09/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Rockwell Medical

 PRESS RELEASE

Rockwell Medical Announces Upcoming Poster Presentation at the Nationa...

Rockwell Medical Announces Upcoming Poster Presentation at the National Home Infusion Association’s 2022 Annual Conference WIXOM, Mich., March 09, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced a poster presentation at the , to be held March 12-16 in Nashville, Tennessee. Details of the poster presentation are as follows: Title: Management of Iron Deficienc...

 PRESS RELEASE

Rockwell Medical, Inc. to Present at Aegis Virtual Conference

Rockwell Medical, Inc. to Present at Aegis Virtual Conference WIXOM, Mich., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that the company is scheduled to present at , on Wednesday, February 23rd at 1:30 - 2:00 PM ET. A recording of the presentation will be posted to the after the conference. The presentation will also be available by request to Aegis from Februa...

 PRESS RELEASE

Rockwell Medical Announces Inducement Grant Under Nasdaq Listing Rule ...

Rockwell Medical Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) WIXOM, Mich., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that a majority of the independent directors serving on the Company’s Board of Directors approved an option grant to a new employee to purchase 10,000 shares of the Company’s common stock (the “Inducement Grant”). The Inducement Grant has been gran...

 PRESS RELEASE

Rockwell Medical Announces Regulatory Approval of Triferic® Dialysate ...

Rockwell Medical Announces Regulatory Approval of Triferic® Dialysate in South Korea Two product forms of Triferic® are now approved in South Korea WIXOM, Mich., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management worldwide, today announced that its partner in South Korea, Jeil Pharmaceutical Co., Ltd. (“Jeil”), has received a second regulatory approval by the Ministry of Food and Drug Safety of the Republic of Korea for Triferic® Dialysate (ferric pyrophosph...

 PRESS RELEASE

Rockwell Medical Announces Regulatory Approval of Triferic® AVNU in So...

Rockwell Medical Announces Regulatory Approval of Triferic® AVNU in South Korea -Commercial launch expected in June/July 2022- -Rockwell Medical has an exclusive license agreement with Jeil Pharmaceutical Co., Ltd., for the rights to Triferic® and Triferic® AVNU in South Korea- -More than 82,000 patients receiving hemodialysis annually in So. Korea- WIXOM, Mich., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and i...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch